<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264210</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO1003</org_study_id>
    <secondary_id>wsy004</secondary_id>
    <nct_id>NCT02264210</nct_id>
  </id_info>
  <brief_title>Icotinib for Completed Resected IB NSCLC With EGFR Mutation</brief_title>
  <acronym>CORIN</acronym>
  <official_title>A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well icotinib works in treating patients with completely&#xD;
      resected stage IB NSCLC harboring EGFR mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adjuvant chemotherapy have shown little evidence of survival benefit in patients with stages&#xD;
      IB non-small cell lung cancer (NSCLC) after complete resection. Epidermal growth factor&#xD;
      receptor tyrosine kinase inhibitors (EGFR-TKIs) show great efficacy in patients with EGFR&#xD;
      mutant non-small cell lung cancer (NSCLC). Icotinib is a novel EGFR-TKI developed by a group&#xD;
      of Chinese scientists and clinician. In the phase III ICOGEN trial, icotinib had&#xD;
      non-inferiority efficacy to gefitinib with better safety. This study is studying icotinib to&#xD;
      see how well it works in treating patients with fully resected stage IB NSCLC harboring EGFR&#xD;
      mutation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>From randomization to the time of disease recurrence or death as a result of any cause, assessed up to 5 years</time_frame>
    <description>DFS will be estimated by the method of Kaplan-Meier</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From randomization to the time of death as a result of any cause, assessed up to 5 years</time_frame>
    <description>OS will be estimated by the method of Kaplan-Meier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The NCI Common Terminology Criteria for Adverse Events version 3.0 will be used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Adenocarcinoma of the Lung</condition>
  <condition>Adenosquamous Cell Lung Cancer</condition>
  <condition>Large Cell Lung Cancer</condition>
  <condition>Bronchial Neoplasms</condition>
  <condition>Stage IB Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Icotinib</intervention_name>
    <description>Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>BPI-2009</other_name>
    <other_name>Conmana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
          -  Males or females, Aged 18-75 years.&#xD;
&#xD;
          -  Able to comply with the required protocol and follow-up procedures, and able to&#xD;
             receive oral medications.&#xD;
&#xD;
          -  Had completely resected pathological confirmed stage IIA-IIIA NSCLC.&#xD;
&#xD;
          -  EGFR activating mutation in exon 19 or 21.&#xD;
&#xD;
          -  Patient who can start the investigational therapy within 3-6 weeks after the complete&#xD;
             resection.&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Had a life expectancy of 12 weeks or more.&#xD;
&#xD;
          -  Adequate hematological function, adequate liver function and renal function.&#xD;
&#xD;
          -  Female patients, except those who are postmenopausal or surgically sterilized, must&#xD;
             have a negative pre-study serum or urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g.&#xD;
             erlotinib, gefitinib, cetuximab, trastuzumab).&#xD;
&#xD;
          -  Inability to comply with protocol or study procedures.&#xD;
&#xD;
          -  Had a history another malignancy in the last 5 years with the exception of cured basal&#xD;
             cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured&#xD;
             epithelial carcinoma of the bladder.&#xD;
&#xD;
          -  Any evidence confirmed tumor recurrence before investigational therapy.&#xD;
&#xD;
          -  Known severe hypersensitivity to icotinib or any of the excipients of this product.&#xD;
&#xD;
          -  Evidence of clinically active interstitial lung disease.&#xD;
&#xD;
          -  Eye inflammation not fully controlled or conditions predisposing the subject to this.&#xD;
&#xD;
          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,&#xD;
             unstable angina, congestive heart failure, myocardial infarction within the previous 6&#xD;
             months, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic&#xD;
             disease).&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Pregnancy or breast-feeding women.&#xD;
&#xD;
          -  Ingredients mixed with small cell lung cancer patients.&#xD;
&#xD;
          -  History of neurologic or psychiatric disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Si-Yu Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Province Association Study of Thoracic Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Si-Yu Wang, MD</last_name>
    <phone>+86 20 87343314</phone>
    <email>wsysums@163.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Yu Wang, Doctor</last_name>
      <phone>+86 20 87343439</phone>
      <email>wsysums@163.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Si-Yu Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
    <mesh_term>Bronchial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

